After Astellas Pharma (ALPMF) and Poseida Therapeutics (PSTX) announced that Xyphos Biosciences, a wholly owned subsidiary of Astellas, and Poseida have entered into a research collaboration and license agreement to develop novel convertibleCAR programs by combining the cell therapy platforms from each of the companies, William Blair analyst Sami Corwin said the firm views the additional collaboration “favorably” as it will provide additional non-dilutive capital, further validates Poseida’s platform and allows the company “to foray into the universal CAR space.” The firm has an Outperform rating on Poseida shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTX:
- Poseida Therapeutics Strikes Major CAR-T Therapy Collaboration Deal
- Poseida Therapeutics management to meet with Piper Sandler
- Poseida Therapeutics Shares Genetic Medicine R&D Insights
- Poseida Therapeutics files to sell 8.33M shares of common stock for holders
- Poseida Therapeutics Unveils Cancer Research Breakthroughs at AACR